GSK3858279, an anti-CCL17 monoclonal antibody, has shown efficacy in relieving osteoarthritis-associated pain [85], and CXCL9 inhibition has demonstrated therapeutic potential in ulcerative colitis [86]. Here, CXCL9 is linked to osteoarthritis.